Product Name | 17-GMB-APA-GA |
Description |
Hsp90 inhibitor |
Purity | >98% |
Molecular Formula | C39H53N5O11 |
Molecular Weight | 767.9 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | Soluble in DMSO (>25 mg/ml) and ethanol (10 mg/ml) |
Source | Synthetic |
Appearance | Purple Solid |
SMILES | O=C/1C2=C(/C(=O)C=C1NC(=O)C(=CC=C[C@H](OC)[C@@H](OC(=O)N)C(=C/[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)C2)/C)C)NCCCNC(=O)CCCN3C(=O)C=C/C3=O |
InChI | InChI=1S/C39H53N5O11/c1-22-18-26-34(42-16-9-15-41-31(46)12-8-17-44-32(47)13-14-33(44)48)28(45)21-27(36(26)50)43-38(51)23(2)10-7-11-29(53-5)37(55-39(40)52)25(4)20-24(3)35(49)30(19-22)54-6/h7,10-11,13- |
InChIKey | OPWAYYOLUIAKCJ-DAJJPBRBSA-N |
Safety Phrases |
Classification: Caution: Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection |
Cite This Product | 17-GMB-APA-GA (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-115) |
Alternative Names | [(3R,5S,6R,7S,10S,11S)-21-[3-[4-(2,5-dioxopyrrol-1-yl)butanoylamino]propylamino]-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate |
Research Areas | Cancer, Heat Shock |
PubChem ID | 57370016 |
Scientific Background | 17-GMB-APA-GA is a synthetic analog of geldanamycin engineered with a maleimido moiety, enabling its use in the development of immunoconjugates. While its primary application has been in targeted cancer therapies, its potential in neuroscience lies in its ability to selectively bind HSP90, a chaperone protein implicated in neurodegenerative disease pathways. By facilitating the targeted delivery of HSP90 inhibitors to specific cell types, 17-GMB-APA-GA may offer a novel strategy for modulating proteostasis in neural tissues. This targeted approach could enhance the clearance of misfolded proteins such as alpha-synuclein and tau, which are central to the pathology of Parkinson’s and Alzheimer’s diseases. Although further research is needed to validate its efficacy in neural models, 17-GMB-APA-GA represents a promising tool for precision medicine in neurodegeneration. |
References |
1. Mandler R., et al. (2004) Cancer Res. 64: 1460. 2. Mandler R., et al. (2002) Bioconj. Chem. 13: 786. 3. Mandler R., et al. (2000) J. Natl. Cancer Inst. 92: 1573. |
Reviews
There are no reviews yet.